A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blockade of inhibitory killer-cell immunoglobulin receptor (KIR) receptors induces augmented NK-cell mediated tumor cell lysis (Romagne F et al., Blood 2009). Hypomethylating agents (HMAs) possess anti-leukemia activity, and increase MHC II expression, cancer antigen exposure in solid and hematologic malignancies, and interferon-gamma signature. KIR-receptor blockade by lirilumab (KIR2DL1/2/3-antibody) may improve responses to HMAs.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Naval Daver, Prajwal Boddu, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Courtney DiNardo, Marina Konopleva, Naveen Pemmaraju, Tapan Kadia, Nitin Jain, Sherry Pierce, Nawar Hussain, Jing Ning, Graciela Nogueras-Gonzalez, Sreyashi Basu, Jorge Cortes, P Source Type: research